Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021. https://t.co/rp7TT6nTMA https://t.co/Zk73M6OUqO

Closing a Chapter: Interview with Dr. David Karp, 84th ACR President 2020-2021 https://t.co/GuE9NdkHlN https://t.co/8e2cUO7Qs3

Tofacitinib and Malignancy Risk Dr. David Liew interviews Dr. Seoyoung Kim at the ACR21 annual meeting. https://t.co/vaoxuy6u5j https://t.co/t3kpMEqy9O

Spondyloarthritis Panel Discussion: ACR21 Meeting https://t.co/lR6zPHKpOo https://t.co/JGsloJUD2t

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting https://t.co/Kpj80YoDmN https://t.co/AChUVw17oc

Download Available! AOSD Disease Patterns Over Time https://t.co/qZBtCQ2QAg https://t.co/fMmN1PAzFG

TNF inhibitors and radiographic progression in axSpA A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease. https://t.co/Gn9vFlq0Bd https://t.co/CXdlU0HQG8

ICYMI:Methotrexate and hepatic fibrosis: we must be doing something right Despite methotrexate’s use in rheumatology, and the consequent frequency of patient counselling about it, relatively little is known about what precautions are absolutely required. https://t.co/AMvnQnMUUl https://t.co/aRzsy4ZA8z

ICYMI: New Insights into Uveitis in Spondyloarthritis Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). Read more on RheumNow. https://t.co/JF7TtE8SVJ https://t.co/Sw2b1WX5ko

ICYMI: Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting. https://t.co/oafDX0rJIl https://t.co/UoNpjABLNd

Guselkemab vs. Ustekinumab in PsA https://t.co/JCs5VpkyUK https://t.co/OzRtdWtqXp